Novartis announced back-to-back pivotal phase III successes with its B cell-targeting antibody ianalumab in Sjögren’s syndrome and primary immune thrombocytopenia (ITP), delivering statistically significant improvements in disease activity and durable platelet maintenance, respectively. These results mark a promising advance for autoimmune disease treatment options, potentially filling unmet medical needs in conditions lacking approved therapies and reinforcing Novartis' position in immunology.